Immunomedics raises $459M as Trodelvy breast cancer launch kicks off amid COVID-19

Launching a drug amid the pandemic is no cakewalk, but Immunomedics decided to do it anyway with first-in-class Trodelvy in triple-negative breast cancer—and it's drummed up some extra money to help. The New Jersey biotech recently closed a $459 million stock offering to help commercialize Trodelvy, expand its clinical programs and scale up manufacturing.